Taiwan's Formosa Pharmaceuticals Signs Licensing Agreement with Israel's Tzamal Biopharma for APP13007

On the 17th, Formosa Pharmaceuticals announced the exclusive licensing of its new drug APP13007 (0.05% Clobetasol Propionate Nanoemulsion Eye Drops) for commercial sales in the Israeli market to Tzamal Biopharma. This licensing agreement includes signing bonuses, development milestones, sales milestones, and other compensations over the contract period.